Evidence map›Paper›PMID 41340120›Full record

ArticleBMC medicine2025

Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression.

Lingling Gao, Jie Jiang, Linlin Zhu, Zhi Xie, Yu Chen, Zhiyi Lv, Yuqing Chen, Wenbin Zhou, Ji Chen, Yumin Zhong and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lingling Gao *Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Jie Jiang *Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Linlin Zhu *Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Zhi Xie *Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Yu ChenMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Zhiyi LvMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Yuqing ChenGuangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Wenbin ZhouMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Ji ChenMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Yumin ZhongMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Li ZhangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Penghui ZengMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Xiaodan HuangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Wenqing YanMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Danxia LuMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Shuilian ZhangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Weibang GuoMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Dongkun ZhangDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Haiyu ZhouDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Weineng FengDepartment of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
Binchao WangGuangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China.
Zunfu KeDepartment of Pathology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangzhou, China.
Xuening YangGuangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China. yangxncn@qq.com.
Hongling LiangDepartment of Breast Oncology Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, 510095, China. lianghonglingu2@163.com.
Xuchao ZhangMedical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Rd., Guangzhou, 510080, China. zhxuchao3000@126.com.

Funding

Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer No. 2017B030314120Guangdong Provincial Natural Science Program No.2019A1515010900, X.ZGuangdong Provincial Natural Science Program No.2022A1515012376, J.HGuangzhou S&T City and University United Project No.2023A03J043, H.LGuangzhou S&T Project No.202102080096, H.LNational Natural Science Foundation of China No.82173202, X.Z
6 · The paper itself

Abstract

backgroundSwitch/sucrose nonfermentable (SWI/SNF) complex mutations have been reported in Kirsten rat sarcoma viral oncogene homologue (KRAS)-mutant non-small cell lung cancer (NSCLC), but the influence on immune checkpoint blockade (ICB) outcomes is debated and needs to be investigated further.

methodsGenomic pathogenic alterations (GPAs) in SWI/SNF genes were identified via OncoKB, COSMIC and PolyPhen-2. NSCLC patients (NSCLCs) were classified according to alterations in six SWI/SNF genes (ARID1A, ARID1B, ARID2, PBRM1, SMARCA4 and SMARCB1). Cell lines used for differentially expressed gene analyses were subjected to RNA sequencing (RNA-seq) and Western blotting to validate protein expression levels. Protein expression in tumour specimens was detected by immunohistochemistry (IHC).

resultsIn 2660 NSCLCs, 15.0% (401/2660) had SWI/SNF GPAs. A total of 23.1% (69/299) of the EGFR

conclusionsIn KRAS-mut NSCLCs with or without STK11/KEAP1 mutations, the GPAs in the DNA-binding genes ARID1A/ARID2 affected the outcomes of immunotherapy, possibly through the downregulation of STING expression.

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsProto-Oncogene Proteins p21(ras)AgedCell Line, TumorChinaDNA-Binding ProteinsDNA HelicasesDown-RegulationEast Asian PeopleFemaleGene Expression Regulation, NeoplasticHumansMaleMembrane ProteinsARID1A protein, humanARID2 protein, humanDNA-Binding ProteinsDNA HelicasesKRAS protein, humanMembrane ProteinsNuclear ProteinsProto-Oncogene Proteins p21(ras)SMARCA4 protein, humanSTING1 protein, humanSTING ProteinTranscription FactorsImmunotherapyKRASNon-small cell lung cancerSWI/SNF

Identifiers

PMID41340120
PMCPMC12781696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.